Enhancing Investor Confidence: Sibble & Associates Debuts Advanced SaaS Product for Comprehensive Technical Due Diligence
CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) — Sibble & Associates, a leading provider of…
News
Sequans Announces Conference Call to Review Second Quarter 2023 Results
Tuesday, August 8, 2023 at 8:00 a.m. ET Paris, France–(Newsfile Corp. – July 24, 2023)…
Ameresco Awarded Top Project of the Year by Environment + Energy Leader for partnership with Holy Cross Energy and Colorado Mountain College
Ameresco’s Solar-plus-storage Project with Holy Cross Energy/Colorado Mountain College Receives Top Project of the Year…
DocGo to Announce Second Quarter 2023 Results on Monday, August 7th
Management to host investor conference call and webcast at 5:00pm EDT on that day NEW…
Ellington Financial Reports Preliminary Results for Second Quarter 2023
OLD GREENWICH, Conn.–(BUSINESS WIRE)–Ellington Financial Inc. (NYSE: EFC) (the “Company”) today disclosed the following estimated…
Public Storage Accelerates Growth with Simply Self Storage Acquisition
GLENDALE, California and New York–(BUSINESS WIRE)–Public Storage (NYSE:PSA) (the “Company”) and Blackstone Real Estate Income…
Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
WALTHAM, Mass., July 24, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical…
Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
WALTHAM, Mass., July 24, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical…
The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch
Press release The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship…
The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch
Press release The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship…
Curia expands biologics capabilities with access to Touchlight’s doggybone DNA
Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to enzymatic…
Curia expands biologics capabilities with access to Touchlight’s doggybone DNA
Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to enzymatic…
BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
Initial topline data from COVALENT-101 trial revealed 2 complete responses (CRs) out of 5 relapsed/refractory…
BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
Initial topline data from COVALENT-101 trial revealed 2 complete responses (CRs) out of 5 relapsed/refractory…
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event
– Live moderated webcast with members of the GRI Bio management team on Thursday, July…
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event
– Live moderated webcast with members of the GRI Bio management team on Thursday, July…
Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors
SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company…
Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors
SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company…
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
Dosing of patients completed at the end of February Data Safety Monitoring Board conducted analysis…
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
Dosing of patients completed at the end of February Data Safety Monitoring Board conducted analysis…